TY - JOUR AU - Reeder, J. G. AU - Vogel, V. G. PY - 2008 DA - 2008// TI - Breast cancer prevention JO - Cancer Treat Res VL - 141 UR - https://doi.org/10.1007/978-0-387-73161-2_10 DO - 10.1007/978-0-387-73161-2_10 ID - Reeder2008 ER - TY - JOUR AU - Dahlman-Wright, K. AU - Cavailles, V. AU - Fuqua, S. A. AU - Jordan, V. C. AU - Katzenellenbogen, J. A. AU - Korach, K. S. PY - 2006 DA - 2006// TI - International union of pharmacology. LXIV. Estrogen receptors JO - Pharmacol Rev VL - 58 UR - https://doi.org/10.1124/pr.58.4.8 DO - 10.1124/pr.58.4.8 ID - Dahlman-Wright2006 ER - TY - JOUR AU - Zagouri, F. AU - Sergentanis, T. N. AU - Nonni, A. AU - Papadimitriou, C. A. AU - Michalopoulos, N. V. AU - Domeyer, P. PY - 2010 DA - 2010// TI - Hsp90 in the continuum of breast ductal carcinogenesis: Evaluation in precursors, preinvasive and ductal carcinoma lesions JO - BMC Cancer VL - 10 UR - https://doi.org/10.1186/1471-2407-10-353 DO - 10.1186/1471-2407-10-353 ID - Zagouri2010 ER - TY - JOUR AU - Gadkar-Sable, S. AU - Shah, C. AU - Rosario, G. AU - Sachdeva, G. AU - Puri, C. PY - 2005 DA - 2005// TI - Progesterone receptors: various forms and functions in reproductive tissues JO - Front Biosci VL - 10 UR - https://doi.org/10.2741/1685 DO - 10.2741/1685 ID - Gadkar-Sable2005 ER - TY - JOUR AU - Mitri, Z. AU - Constantine, T. AU - O’Regan, R. PY - 2012 DA - 2012// TI - The HER2 receptor in breast cancer: Pathophysiology, clinical use, and new advances in therapy JO - Chemother Res Pract VL - 25 ID - Mitri2012 ER - TY - JOUR AU - Clark, S. E. AU - Warwick, J. AU - Carpenter, R. AU - Bowen, R. L. AU - Duffy, S. W. AU - Jones, J. L. PY - 2011 DA - 2011// TI - Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease JO - Br J Cancer VL - 104 UR - https://doi.org/10.1038/sj.bjc.6606021 DO - 10.1038/sj.bjc.6606021 ID - Clark2011 ER - TY - JOUR AU - Mohammed, Z. M. AU - Going, J. J. AU - Edwards, J. AU - Elsberger, B. AU - Doughty, J. C. AU - McMillan, D. C. PY - 2012 DA - 2012// TI - The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer JO - Br J Cancer VL - 107 UR - https://doi.org/10.1038/bjc.2012.347 DO - 10.1038/bjc.2012.347 ID - Mohammed2012 ER - TY - JOUR AU - Domschke, C. AU - Schuetz, F. AU - Ge, Y. AU - Seibel, T. AU - Falk, C. AU - Brors, B. PY - 2009 DA - 2009// TI - Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-09-1627 DO - 10.1158/0008-5472.CAN-09-1627 ID - Domschke2009 ER - TY - JOUR AU - Keibel, A. AU - Singh, V. AU - Sharma, M. C. PY - 2009 DA - 2009// TI - Inflammation, microenvironment, and the immune system in cancer progression JO - Curr Pharm Des VL - 15 UR - https://doi.org/10.2174/138161209788453167 DO - 10.2174/138161209788453167 ID - Keibel2009 ER - TY - JOUR AU - Schmidt, C. PY - 2006 DA - 2006// TI - Immune system’s Toll-like receptors have good opportunity for cancer treatment JO - J Nat Cancer Inst VL - 98 UR - https://doi.org/10.1093/jnci/djj198 DO - 10.1093/jnci/djj198 ID - Schmidt2006 ER - TY - JOUR AU - Ruffell, B. AU - Au, A. AU - Rugo, H. S. AU - Esserman, L. J. AU - Hwang, E. S. AU - Coussens, L. M. PY - 2011 DA - 2011// TI - Leukocyte composition of human breast cancer JO - Proc Natl Acad Sci U S A VL - 109 UR - https://doi.org/10.1073/pnas.1104303108 DO - 10.1073/pnas.1104303108 ID - Ruffell2011 ER - TY - JOUR AU - Sas, L. AU - Lardon, F. AU - Vermeulen, P. B. AU - Hauspy, J. AU - Dam, P. V. AU - Pauwels, P. PY - 2012 DA - 2012// TI - The interaction between ER and NF-κB in resistance to endocrine therapy JO - Breast Cancer Res VL - 14 UR - https://doi.org/10.1186/bcr3196 DO - 10.1186/bcr3196 ID - Sas2012 ER - TY - JOUR AU - Belguise, K. AU - Sonenshein, G. E. PY - 2007 DA - 2007// TI - PKCθ promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor α synthesis JO - J Clin Invest VL - 117 ID - Belguise2007 ER - TY - JOUR AU - Reijm, E. A. AU - Jansen, M. P. AU - Ruigrok-Ritstier, K. AU - Staveren, I. L. AU - Look, M. P. AU - Gelder, M. E. PY - 2011 DA - 2011// TI - Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer JO - Breast Cancer Res Treat VL - 125 UR - https://doi.org/10.1007/s10549-010-0836-9 DO - 10.1007/s10549-010-0836-9 ID - Reijm2011 ER - TY - JOUR AU - Wang, X. AU - Belguise, K. AU - O’Neill, C. F. AU - Sánchez-Morgan, N. AU - Romagnoli, M. AU - Eddy, S. F. PY - 2009 DA - 2009// TI - RelB NF-κB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1 JO - Mol Cell Biol VL - 29 UR - https://doi.org/10.1128/MCB.00032-09 DO - 10.1128/MCB.00032-09 ID - Wang2009 ER - TY - JOUR AU - Orange, J. S. AU - Levy, O. AU - Geha, R. S. PY - 2005 DA - 2005// TI - Human disease resulting from gene mutations that interfere with appropriate nuclear factor-kappaB activation JO - Immunol Rev VL - 203 UR - https://doi.org/10.1111/j.0105-2896.2005.00221.x DO - 10.1111/j.0105-2896.2005.00221.x ID - Orange2005 ER - TY - JOUR AU - Werner, A. B. AU - Vries, E. AU - Tait, S. W. AU - Bontjer, I. AU - Borst, J. PY - 2002 DA - 2002// TI - Bcl-2 family member Bfl-1/A1 sequesters truncated bid to inhibit is collaboration with pro-apoptotic Bak or Bax JO - J Biol Chem VL - 277 UR - https://doi.org/10.1074/jbc.M201469200 DO - 10.1074/jbc.M201469200 ID - Werner2002 ER - TY - JOUR AU - Chipuk, J. E. AU - Moldoveanu, T. AU - Llambi, F. AU - Parsons, M. J. AU - Green, D. R. PY - 2010 DA - 2010// TI - The BCL-2 family reunion JO - Mol Cell VL - 37 UR - https://doi.org/10.1016/j.molcel.2010.01.025 DO - 10.1016/j.molcel.2010.01.025 ID - Chipuk2010 ER - TY - STD TI - Martin LA, Dowsett M. BCL-2: A New Therapeutic Target in Estrogen Receptor-Positive Breast Cancer? 2013;24(1):7–9. doi: 10.1016/j.ccr.2013.06.006. ID - ref19 ER - TY - JOUR AU - Berezowska, S. AU - Novotny, A. AU - Bauer, K. AU - Feuchtinger, A. AU - Slotta-Huspenina, J. AU - Becker, K. PY - 2013 DA - 2013// TI - Association between HSP90 and Her2 in Gastric and Gastroesophageal Carcinomas JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0069098 DO - 10.1371/journal.pone.0069098 ID - Berezowska2013 ER - TY - JOUR AU - Lang, S. A. AU - Klein, D. AU - Moser, C. AU - Gaumann, A. AU - Glockzin, G. PY - 2007 DA - 2007// TI - Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo JO - Mol Cancer Ther VL - 6 UR - https://doi.org/10.1158/1535-7163.MCT-06-0628 DO - 10.1158/1535-7163.MCT-06-0628 ID - Lang2007 ER - TY - JOUR AU - Koga, P. AU - Xu, W. AU - Karpova, T. S. PY - 2006 DA - 2006// TI - Hsp90 inhibition transiently activates Sic kinase ami promotes Src-dependent Akt and Erk activation JO - Proc Natl Acad Sci U S A VL - 103 UR - https://doi.org/10.1073/pnas.0604705103 DO - 10.1073/pnas.0604705103 ID - Koga2006 ER - TY - JOUR AU - Eustace, B. K. AU - Sakurai, T. AU - Stewart, J. K. AU - Yimlamai, D. AU - Unger, C. AU - Zehetmeier, C. PY - 2004 DA - 2004// TI - Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness JO - Nat Cell Biol VL - 6 UR - https://doi.org/10.1038/ncb1131 DO - 10.1038/ncb1131 ID - Eustace2004 ER - TY - JOUR AU - Kregel, K. C. PY - 2002 DA - 2002// TI - Ileal shock proteins: modifying factors in physiological stress responses and acquired Ihemiotolerance JO - J Appl Physiol VL - 92 UR - https://doi.org/10.1152/japplphysiol.01267.2001 DO - 10.1152/japplphysiol.01267.2001 ID - Kregel2002 ER - TY - JOUR AU - Workman, P. PY - 2004 DA - 2004// TI - Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone JO - Cancer Lett VL - 206 UR - https://doi.org/10.1016/j.canlet.2003.08.032 DO - 10.1016/j.canlet.2003.08.032 ID - Workman2004 ER - TY - JOUR AU - Grad, I. AU - Picard, D. PY - 2007 DA - 2007// TI - The glucocorticoid responses are shaped by molecular chaperones JO - Mol Cell Endocrin VL - 275 UR - https://doi.org/10.1016/j.mce.2007.05.018 DO - 10.1016/j.mce.2007.05.018 ID - Grad2007 ER - TY - JOUR AU - Dawson, S. J. AU - Makretsov, N. AU - Blows, F. M. AU - Driver, K. E. AU - Provenzano, E. AU - Quesne, J. PY - 2010 DA - 2010// TI - BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received JO - Br J Cancer VL - 103 UR - https://doi.org/10.1038/sj.bjc.6605736 DO - 10.1038/sj.bjc.6605736 ID - Dawson2010 ER - TY - JOUR AU - Vaillant, F. AU - Merino, D. AU - Lee, L. AU - Breslin, K. AU - Pall, B. AU - Ritchie, M. E. PY - 2013 DA - 2013// TI - Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer JO - Cancer Cell VL - 24 UR - https://doi.org/10.1016/j.ccr.2013.06.002 DO - 10.1016/j.ccr.2013.06.002 ID - Vaillant2013 ER - TY - JOUR AU - Lindeman, G. J. AU - Visvader, J. E. PY - 2013 DA - 2013// TI - Targeting BCL-2 in breast cancer: exploiting a tumor lifeline to deliver a mortal blow? JO - Breast Cancer Manage VL - 2 UR - https://doi.org/10.2217/bmt.12.60 DO - 10.2217/bmt.12.60 ID - Lindeman2013 ER - TY - JOUR AU - Souers, A. J. AU - Leverson, J. D. AU - Boghaert, E. R. AU - Ackler, S. L. AU - Catron, N. D. AU - Chen, J. PY - 2013 DA - 2013// TI - ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets JO - Nat Med VL - 19 UR - https://doi.org/10.1038/nm.3048 DO - 10.1038/nm.3048 ID - Souers2013 ER - TY - JOUR AU - Huang, Z. PY - 2000 DA - 2000// TI - Bcl-2 family proteins as targets for anticancer drug design JO - Oncogene VL - 19 UR - https://doi.org/10.1038/sj.onc.1204087 DO - 10.1038/sj.onc.1204087 ID - Huang2000 ER -